Hybrid PET MRI Systems Market (2026 - 2033)

Hybrid PET MRI Systems Market Summary

The global hybrid PET MRI systems market size was valued at USD 473.9 million in 2025 and is projected to grow from USD 485.8 million in 2026 to USD 599.4 million by 2033, at a CAGR of 3.0% from 2026 to 2033. North America dominated the market, accounting for the revenue share of 41.3% in 2025. The industry is experiencing strong growth, driven by the increasing adoption of advanced multimodal imaging technologies, rising demand for precise and early disease diagnosis, and growing applications in oncology, neurology, and cardiology.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

To learn more about this report, Download Free Sample Report

Hybrid PET/MRI (positron emission tomography/magnetic resonance imaging) systems combine simultaneous functional and anatomical imaging in a single examination, a capability the FDA classifies as a Class II medical device under 21 CFR 892.1200, product code OUO. Since the first U.S. clearance in 2011, fourteen PET/MR systems have received FDA 510(k) clearance, spanning four manufacturers. Over the same period, federal health agencies have tracked a growing burden of the two disease categories. PET/MR is most often used to evaluate cancer and neurodegenerative disease, while CMS has progressively simplified Medicare’s coverage rules for PET-based diagnosis.

To learn more about this report, Download Free Sample Report

The National Cancer Institute’s SEER Program, the U.S. government’s authoritative source for population-based cancer statistics, projected 2,041,910 new cancer cases and 618,120 cancer deaths in the United States in 2025 across all sites. Within that total, several specific cancer types carry particular relevance to PET/MR: brain and other nervous-system cancers, where SEER projected 24,820 new cases and 18,330 deaths in 2025, with 187,162 Americans living with a brain or CNS cancer diagnosis as of 2022; and the two most commonly diagnosed solid tumors, female breast cancer (316,950 new cases, 42,170 deaths) and prostate cancer (313,780 new cases, 35,770 deaths) in 2025. PET/MR’s ability to fuse metabolic activity with high-resolution soft-tissue anatomy is particularly suited to brain tumor delineation and to monitoring treatment response in cancers where sequential PET and MRI exams were previously required.

On the neurology side, CDC’s National Center for Health Statistics recorded Alzheimer’s disease as the sixth-leading cause of death in the United States across all ages in 2023, with 114,034 recorded deaths, a burden that continues to grow as the U.S. population ages. Emerging Alzheimer’s drug therapies increasingly rely on PET imaging to confirm diagnosis before treatment and on MR imaging to monitor for treatment-related side effects. A combination hybrid PET/MR performs in a single simultaneous session rather than two separate appointments.

To learn more about this report, Download Free Sample Report

Because the FDA’s 510(k) database records the applicant on every clearance, it is possible to build a complete, non-proprietary picture of which companies have brought hybrid PET/MR systems to the U.S. market and how often.

Siemens Healthineers (filing under both Siemens Medical Solutions U.S. and, most recently, Siemens Healthineers AG) holds six of the fourteen clearances on record, the most of any applicant. Its clearance history begins with the Biograph mMR (K103429, 2011) and continues through several hardware and software updates to that platform (K133226 in 2013, K163234 in 2017, K172531 in 2017, K200213 in 2020) before culminating in the Biograph One (K253023), a second-generation PET/MR platform cleared in January 2026 the most recent filing in the category and Siemens’ first ground-up PET/MR refresh since the original Biograph mMR fourteen years earlier.

Shanghai United Imaging Healthcare holds four clearances, all under the same device name, uPMR 790, filed in February 2019, November 2019, November 2022, and May 2024, a cadence suggesting iterative updates to a single platform rather than a new product line each time. GE Medical Systems (doing business as GE HealthCare) holds three clearances for its SIGNA PET/MR system, filed in November 2014, February 2017, and January 2022. Philips Healthcare (Cleveland) holds a single clearance, the Ingenuity TF PET/MR (K103483), cleared in November 2011 alongside Siemens’ original Biograph mMR and not updated in the FDA’s OUO record since.

To learn more about this report, Download Free Sample Report

Market Dynamics

The hybrid PET MRI systems market is being supported by the increasing demand for advanced multimodal imaging, growing prevalence of cancer and neurological disorders, rising need for accurate disease diagnosis and staging, and technological advancements in PET and MRI platforms. PET/MRI combines the molecular and functional information of positron emission tomography with the high soft-tissue contrast of magnetic resonance imaging, enabling comprehensive assessment within a single examination. Increasing adoption in oncology, neurology, cardiology, and pediatric imaging, along with improvements in image reconstruction, artificial intelligence, and system integration, is also supporting market development.

Market Concentration & Characteristics

The hybrid PET MRI systems market is characterized by a relatively concentrated competitive landscape, with established medical-imaging manufacturers accounting for much of the clinical PET/MRI ecosystem, alongside specialized companies serving research and niche applications. The market operates across clinical and research pathways, with PET/MRI combining molecular and metabolic information from PET with MRI-based anatomical and soft-tissue characterization. The U.S. FDA classifies PET/MRI as a Class II medical device under product code OUO, with a 510(k) premarket pathway. The FDA classification page was updated on September 14, 2026.

The industry is characterized by continued innovation in PET detector technology, time-of-flight imaging, AI-enabled reconstruction, motion correction, attenuation correction, quantitative imaging, and MRI workflow optimization. Innovation is increasingly focused on improving image quality while reducing acquisition time and simplifying complex PET/MRI workflows. Manufacturers are also developing technologies that improve scanner usability and reduce infrastructure requirements. A notable development occurred in January 2026, when Siemens Healthineers received FDA clearance for Biograph One, a second-generation PET/MR scanner combining anatomical and functional imaging. The company highlighted AI-powered image reconstruction and simplified workflows, with applications including oncology and neurological diseases.

Innovation is also extending toward advanced quantitative PET imaging. In May 2026, GE HealthCare announced that its MIM KineticID software had become 510(k)-pending with the FDA, supporting dynamic PET workflows and kinetic modeling designed to evaluate tracer behavior over time.

To learn more about this report, Download Free Sample Report

Partnerships and collaborations are becoming increasingly important as PET/MRI requires coordination among imaging-equipment manufacturers, hospitals, academic institutions, nuclear medicine departments, radiologists, physicists, and research organizations. Collaboration supports clinical validation, radiotracer research, workflow development, technology evaluation, and expansion of PET/MRI applications.

Academic medical centers are particularly important because PET/MRI remains a specialized modality requiring substantial clinical expertise and infrastructure. Government procurement records also demonstrate continued investment in PET/MRI infrastructure. For example, in February 2025, China's government procurement platform reported a contract worth approximately RMB 8.0 million for renovation work associated with the PET/MR and SPECT/CT rooms at Huashan Hospital, Fudan University.

Regulation has a significant impact on the hybrid PET MRI systems market because PET/MRI systems combine two regulated imaging technologies and require compliance with medical-device, radiation-safety, MRI-safety, and quality-management requirements. In the U.S., the FDA classifies PET/MRI as a Class II device, with the 510(k) pathway applying to these systems. The FDA's guidance for MRI diagnostic devices also specifically applies to MRI components incorporated into dual-modality devices such as PET/MRI systems. A recent regulatory development occurred in February 2026, when the FDA's updated Quality Management System Regulation (QMSR) became effective. The regulation incorporates ISO 13485:2016 into the U.S. medical-device quality framework, affecting manufacturers' quality-management and compliance processes.

The regulatory environment also influences product modifications and post-market monitoring. FDA records updated in 2026 continue to list SIGNA PET/MR under the Class II PET/MRI classification, demonstrating ongoing regulatory oversight of commercially deployed systems.

The hybrid PET MRI systems market faces substitution from PET/CT, standalone MRI, standalone PET, SPECT/CT, and other conventional or hybrid diagnostic imaging modalities. PET/CT remains an important alternative because it combines metabolic information with anatomical imaging and has a substantially established clinical workflow. MRI can also substitute for PET/MRI when high-resolution soft-tissue characterization is required without molecular PET information.

Substitution varies according to disease, clinical objective, availability, cost, radiation considerations, and institutional capabilities. PET/MRI can provide advantages in selected applications requiring complementary molecular and soft-tissue information, particularly oncology, neurology, and pediatric imaging. However, high capital costs, longer examination workflows, radiotracer requirements, and specialized infrastructure can influence modality selection. The FDA describes PET/MRI as an integrated system capable of acquiring PET and MR images simultaneously or sequentially, with MRI data also used for PET attenuation correction.

Regional expansion in the market is being supported by increasing investment in advanced diagnostic infrastructure, modernization of hospital imaging departments, and expansion of PET, MRI, and nuclear medicine capabilities. In the U.S., GE HealthCare and Catholic Health announced a USD 500 million, 10-year partnership in July 2026, covering MR, PET, nuclear medicine, and AI-enabled imaging across multiple healthcare locations. In Australia, NSW Health reported in May 2026 that Nepean Hospital received advanced MRI, CT, and molecular-imaging equipment as part of a more than AUD 1 billion redevelopment, strengthening diagnostic capacity for oncology, cardiac, and neurological care. These investments demonstrate the broader expansion of the infrastructure supporting advanced hybrid imaging technologies.

Analyst Perspective

The hybrid PET MRI systems market is expected to witness steady growth, supported by increasing demand for advanced multimodal imaging, rising cancer burden, and expanding applications in oncology, neurology, and cardiology. From an analyst perspective, the market is evolving toward digital PET detectors, improved time-of-flight performance, AI-enabled image reconstruction, and enhanced motion and attenuation correction capabilities. Established players such as Siemens Healthineers, GE HealthCare, Philips, and United Imaging Healthcare are strengthening their portfolios through technological advancements and clinical applications.

Type Insights

The traditional PET-MRI systems segment dominated the market in 2025, accounting for 72.1% of overall market revenue. Its leading position is primarily attributed to the established clinical adoption of conventional PET-MRI platforms, broader availability across major hospitals and academic medical centers, and extensive use in oncology, neurology, and cardiovascular imaging. Traditional systems benefit from proven imaging performance, established clinical workflows, and a growing body of evidence supporting their diagnostic utility. In addition, established manufacturers such as Siemens Healthineers, GE HealthCare, and Philips have supported market penetration through advanced PET/MRI platforms, software integration, and technological improvements in image reconstruction, motion correction, and attenuation correction.

The helium-free PET-MRI systems segment is expected to witness steady growth, supported by increasing demand for simplified MRI infrastructure, reduced dependence on liquid helium, and more efficient installation and operating requirements. Helium-free magnet technologies can help healthcare facilities address challenges associated with helium supply, storage, and cooling infrastructure while potentially reducing system footprint and maintenance requirements. Growing investments in advanced diagnostic imaging, particularly across hospitals, academic medical centers, and specialized imaging facilities, are creating opportunities for adoption. In addition, continued technological advancements in compact magnet designs, system integration, and PET detector technologies are expected to improve the feasibility and commercial attractiveness of helium-free PET-MRI platforms over the forecast period.

Application Insights

The oncology segment dominated the hybrid PET MRI systems market in 2025, underpinned by the growing demand for accurate cancer detection, staging, treatment planning, and therapy-response assessment. PET/MRI combines PET-based metabolic and molecular information with MRI’s superior soft-tissue contrast, enabling comprehensive evaluation of primary tumors, lymph-node involvement, and metastatic disease. Increasing cancer incidence worldwide, along with the expanding use of precision oncology and molecular imaging, is strengthening demand for advanced multimodal diagnostic technologies. PET/MRI is particularly valuable for brain, head and neck, pelvic, pediatric, and other soft-tissue malignancies. Continued improvements in image reconstruction, motion correction, and quantitative imaging are further supporting oncology applications.

The neurology segment is expected to witness significant growth, driven by increasing demand for advanced brain imaging and growing clinical applications in neurodegenerative diseases, epilepsy, brain tumors, and dementia. PET/MRI enables simultaneous assessment of molecular, metabolic, structural, and functional changes, providing complementary information that can support disease characterization and treatment planning. Rising neurological disease burden and expanding research into biomarkers are further encouraging adoption across specialized hospitals and academic institutions. Technological advancements in high-resolution MRI, PET detectors, motion correction, and quantitative image analysis are improving diagnostic capabilities. Increasing clinical evidence and research activity are expected to further strengthen PET/MRI utilization in neurology.

End-use Insights

The hospitals segment held the largest revenue share of the hybrid PET MRI systems market in 2025, strenghtened by the availability of advanced diagnostic infrastructure, substantial capital investment capabilities, and access to multidisciplinary clinical expertise. Hospitals increasingly adopt PET/MRI systems for complex oncology, neurological, cardiovascular, and pediatric imaging applications requiring comprehensive anatomical and molecular information. In addition, tertiary-care and academic hospitals serve as major centers for advanced diagnostic procedures, clinical research, and technology evaluation, encouraging investments in sophisticated imaging platforms. Growing patient volumes, increasing emphasis on precision diagnosis, and technological advancements in PET/MRI systems are further supporting adoption across hospitals globally.

To learn more about this report, Download Free Sample Report

The diagnostic imaging centers segment is expected to witness the fastest growth over the forecast period, driven by the increasing demand for advanced outpatient diagnostic services, expansion of specialized imaging facilities, and growing adoption of multimodal imaging technologies. PET/MRI systems offer comprehensive anatomical and molecular information in a single examination, supporting applications across oncology, neurology, and other complex diagnostic areas. Rising healthcare expenditure, increasing patient preference for outpatient imaging, and investments in advanced diagnostic infrastructure are encouraging imaging centers to expand their technological capabilities. In addition, improvements in PET detectors, AI-assisted image reconstruction, motion correction, and workflow optimization are expected to enhance system efficiency and support wider adoption.

Regional Insights

Thehybrid PET MRI systems industry in North Americaaccounted for 41.3% share of the global market in 2025, supported by advanced nuclear medicine and MRI infrastructure, high healthcare expenditure, established academic medical centers, and strong multimodal imaging research. In the U.S., the National Cancer Institute estimated 2.04 million new cancer cases in 2025, supporting demand for advanced oncology imaging. Canada is also characterized by a substantial cancer burden, with 254,800 new cancer cases projected for 2025, while approximately 42% of Canadians are expected to develop cancer during their lifetime. These factors support PET/MRI applications across oncology, neurology, and pediatric imaging.

To learn more about this report, Download Free Sample Report

U.S. Hybrid PET MRI Systems Market Trends

Thehybrid PET MRI systems industry in the U.S. is well-positioned due to the large installed base of advanced diagnostic imaging equipment, leading academic hospitals, and strong clinical research capabilities. PET/MRI applications continue to expand in oncology, neurology, and pediatric imaging, where MRI's superior soft-tissue characterization can complement PET's molecular information. A 2025 Radiographics publication specifically reviewed PET/MRI techniques, indications, and clinical implementation in pediatric patients, highlighting its relevance for reducing radiation exposure and improving soft-tissue assessment.

Europe Hybrid PET MRI Systems Market Trends

The hybrid PET MRI systems industry in Europe is supported by developed healthcare systems, established nuclear medicine departments, advanced MRI infrastructure, and increasing emphasis on precision diagnosis. Adoption varies across countries according to healthcare budgets, reimbursement policies, availability of radiotracers, and access to specialized imaging centers. Technological advancements, improved image reconstruction, integration of artificial intelligence, and increasing research activities are further supporting market expansion.

The UKhybrid PET MRI systems industryis characterized by an established NHS diagnostic-imaging infrastructure and increasing emphasis on advanced imaging for cancer and other complex diseases. PET/MRI remains a specialized modality, with adoption concentrated in major hospitals and academic centers. Continued research into PET-based quantitative imaging and radiation oncology is supporting the clinical evidence base for advanced PET applications.

The hybrid PET MRI systems industry in Germany benefits from a highly developed healthcare system, strong medical-technology capabilities, and extensive research infrastructure. Demand for hybrid imaging is supported by oncology and neurological applications, particularly at university hospitals and specialized imaging centers. The country's strong academic and research ecosystem also provides opportunities for PET/MRI development, clinical validation, and molecular-imaging research.

The Spain hybrid PET MRI systems industry is supported by established hospital-based nuclear medicine services, specialist radiology departments, and growing adoption of advanced multimodal imaging. PET/MRI remains concentrated in specialized centers because of its high capital requirements and complex workflow. Continued development of oncology imaging, neurological applications, and research programs is creating opportunities for further utilization of integrated PET/MRI systems.

Asia Pacific Hybrid PET MRI Systems Market Trends

The hybrid PET MRI systems industryin the Asia Pacific is expected to exhibit the fastest CAGR during the forecast period. The growth comes on the back of the prevalence of significant development opportunities due to expanding healthcare infrastructure, increasing cancer and neurological disease burden, and rising investment in advanced diagnostic imaging. China and Japan have developed substantial PET and MRI capabilities, while other markets are gradually increasing access to sophisticated molecular imaging. Government-supported healthcare investment and academic research are expected to support the adoption of hybrid imaging technologies.

The Chinahybrid PET MRI systems industryhas gained impetus from the expanding advanced imaging infrastructure and increasing research activity in PET/MR applications. A notable government-affiliated example is Beijing Xuanwu Hospital, which in September 2025 marked the 10th anniversary of its PET/MR installation with a symposium focused on brain function and molecular imaging. The event demonstrates the established use of PET/MR for neuroscience and molecular-imaging research in China.

The hybrid PET MRI systems industry in Japan has high hopes on advanced healthcare infrastructure, sophisticated diagnostic imaging capabilities, and established nuclear medicine services. PET imaging reimbursement and regulatory frameworks remain important considerations for market development. In August 2025, Japan's Central Social Insurance Medical Council discussed the need to improve reimbursement pathways for PET diagnostic agents, highlighting the importance of reimbursement and radiotracer availability for expanding PET-based diagnostic services.

Latin America Hybrid PET MRI Systems Market Trends

The hybrid PET MRI systems industry in Latin America is developing alongside improvements in diagnostic imaging infrastructure, cancer-care capacity, and access to nuclear medicine. For instance, Brazil represents an important market due to its relatively large healthcare systems and specialist medical centers. However, high equipment costs, radiotracer availability, reimbursement limitations, and concentration of advanced imaging services in major cities continue to influence PET/MRI adoption.

The Brazilhybrid PET MRI systems industryhas gained prominence due to the increasing utilization of PET-based imaging in oncology and the expansion of advanced diagnostic services. In May 2025, Brazil's Ministry of Health expanded the use of PET/CT within the Unified Health System (SUS) for staging patients with locally advanced esophageal carcinoma following inconclusive CT results. Although the policy concerns PET/CT rather than PET/MRI, it demonstrates increasing government-supported utilization of PET-based molecular imaging in cancer care and provides an infrastructure and clinical-use environment relevant to hybrid PET imaging.

Middle East & Africa Hybrid PET MRI Systems Market Trends

The hybrid PET MRI systems industry in the Middle East & Africa (MEA)has received a major boost from the healthcare infrastructure development, investment in advanced diagnostic centers, and growing demand for oncology and neurological imaging. Adoption remains concentrated in countries with relatively advanced healthcare systems and specialist hospitals. High capital expenditure, limited availability of specialized personnel, radiotracer logistics, and reimbursement constraints remain important considerations for wider PET/MRI deployment.

The Saudi Arabiahybrid PET MRI systems industry is supported by continued development of specialized healthcare infrastructure and investment in advanced diagnostic technologies. PET-based imaging is particularly relevant to the country's expanding cancer-diagnostic capabilities. The adoption of PET/MRI is expected to remain concentrated in major tertiary hospitals and specialized medical centers because of the technology's capital intensity, technical complexity, and requirement for multidisciplinary expertise.

Key Hybrid PET MRI Systems Company Insights

The hybrid PET MRI systems market is competitive, with key players including Siemens Healthineers, GE HealthCare, and Koninklijke Philips N.V. These companies are focusing on product innovation, advanced detector technologies, AI-enabled image reconstruction, improved motion and attenuation correction, and strategic collaborations to strengthen their market presence. Competition is centered on integrated PET/MRI platforms, digital PET technology, helium-free or dry-magnet solutions, improved imaging performance, and expansion across oncology, neurology, cardiovascular, and research applications. Established imaging manufacturers leverage broad healthcare portfolios and hospital networks, while specialized players emphasize preclinical, research, and niche molecular-imaging applications.

Key Hybrid PET MRI Systems Companies

The following key companies have been profiled for this study on the hybrid PET MRI systems market.

• Siemens Healthineers

• GE HealthCare

• Koninklijke Philips N.V.

• United Imaging Healthcare

• Bruker Corporation

• Mediso Ltd.

• MR Solutions

• Canon Medical Systems Corporation

• Cubresa Inc.

• Molecubes

Recent Development

• In June 2026, St. Joseph’s Health Care London unveiled Canada’s first BIOGRAPH One PET/MR at the Lawson Research Institute. The system is expected to support research in oncology, stroke, neurological disorders, chronic pain, and other conditions, strengthening Canada’s advanced hybrid imaging and molecular imaging capabilities.

“This milestone reflects our team’s deep commitment to bringing one of the most advanced imaging technologies to Canada, Seeing BIOGRAPH One installed at Lawson is incredibly rewarding. It shows how innovation can directly support clinicians and researchers in delivering better care and driving new discoveries.”

- Head of MRI business, Siemens Healthineers Canada

“Collaboration is at the heart of what makes achievements like this possible, We’re proud to partner with St. Joseph’s and Lawson to support research that will expand our understanding of disease, including neurodegenerative diseases and Alzheimer’s disease, and ultimately improve patient outcomes across Canada.”

- PhD, head of research, innovation and scientific engagement, Siemens Healthineers Canada.

• In May 2026, United Imaging showcased its latest uPMR Zenith PET/MR system at SNMMI 2026, highlighting high PET sensitivity, advanced MR capabilities, real-time motion imaging, improved time-of-flight resolution, and whole-body imaging. The company also highlighted applications across oncology, neurology, drug development, and theranostics, supporting the expansion of advanced PET/MR technologies in the North American market.

Global Hybrid PET MRI Systems Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global hybrid PET MRI systems market report based on type, application, end-use, and region:

To learn more about this report, Download Free Sample Report

• Type Outlook (Revenue, USD Million, 2021 - 2033)

  • Traditional PET-MRI systems

  • Helium-free PET-MRI systems

• Application Outlook (Revenue, USD Million, 2021 - 2033)

  • Oncology

  • Neurology

  • Cardiovascular

  • Musculoskeletal

  • Others

• End-use Outlook (Revenue, USD Million, 2021 - 2033)

  • Hospitals

  • Diagnostic Imaging Centers

  • Ambulatory Surgery Centers

  • Specialty Clinics & Cath Labs

  • Academic & Research Institutes

• Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • China

    • Japan

    • South Korea

    • India

    • Australia

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • MEA

    • Saudi Arabia

    • South Africa

    • UAE

    • Kuwait

Research Methodology

The hybrid PET MRI systems marketfigures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing-reconciling supply-side and demand-side estimates-and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with eachhybrid PET MRI systemssegment quantified using the revenue-capture definitions in the table below.

Delivered Customizations

This report has been delivered with the following In-depth customizations